New York, USA – March 21, 2022 – In the past few years, the illegal use of β-agonists in livestock production has aroused much attention. Since the U.S. Food and Drug Administration approved ractopamine hydrochloride and zilpaterol hydrochloride in animal feeds, usage of those compounds has been a topic of worldwide debate. Ractopamine and zilpaterol are β agonists used as veterinary drugs to increase weight gain in certain animals raised for food.
However, researchers have indicated that β-agonists can lead to several dose-related severe adverse reactions, including anxiety, tremor, palpitations or fast heart rate, and low blood potassium. To detect β-agonist residues in livestock breeding, a wide variety of antibody-based immunoassays have been developed, among which antibodies generated by new β-agonist haptens are attractive tools for a rapid and accurate immunoassay.
As a professional expert in the field of antibody discovery and novel hapten design, Creative Biolabs has generated a wide-ranging platform and developed efficient protocols for designing and assessing potential β-agonist haptens. Besides, they can also conduct hapten optimization studies by using suitable linker length, various carrier proteins, as well as unique coating antigens. According to different connection sites of β-agonist haptens, Creative Biolabs offers β-agonist haptens design and synthesis services of two types: class-specific β-agonist haptens and compound-specific β-agonist haptens.
Design and Synthesis of Class-specific Haptens for β-agonists
Creative Biolabs provides a one-stop solution hapten-based platform to design and synthesize suitable class-specific haptens for β-agonists, to generate a high affinity and specific antibody, as well as to evaluate the properties of the antibody by using various immunoassays. For instance, a new hapten has been designed to obtain a specific monoclonal antibody against salbutamol (SAL) with an IC50 value of 0.74 ng/mL. Several female BALB/c mice have been immunized with new SAL hapten-keyhole limpet hemocyanin (KLH) conjugate. The data have suggested that this class specificity antibody has similar selectivity for salbutamol and has high cross-reactivity (107%) with other types of β-agonists.
Design and Synthesis of Compound-specific β-agonist Haptens
Compound-specific β-agonist haptens have become optimal options for developing small-molecule antibodies used in immunoassays, such as enzyme-linked immune sorbent assay (ELISA). Creative Biolabs offers a full range of customized compound-specific β-agonist hapten-based services, ranging from β-agonist hapten discovery, β-agonist hapten optimization, β-agonist hapten assessment, to small-molecule antibody development. They have successfully designed several haptens for different β-agonists, such as salbutamol and clenbuterol. Moreover, these haptens have been used for the generation of novel compound-specific antibodies. For instance, a novel antibody against salbutamol generated by Creative Biolabs has shown high sensitivity and a high cross-reactivity (106%) with clenbuterol in heterologous competitive indirect ELISA.
More information about β-agonists Hapten Design and Synthesis can be found at https://small-molecule-antibody.creative-biolabs.com.
About Creative Biolabs
To promote the development of immunoassays for the detection of drug residues, Creative Biolabs launched a center focused on small molecule antibody associated solutions and is always dedicated to assisting worldwide clients with one-stop hapten development services from hapten design, modification and synthesis, to antibody production and optimization.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://small-molecule-antibody.creative-biolabs.com